Daiichi Sankyo ( Daiichi Sankyo )

Daiichi Sankyo

Daiichi Sankyo's picture

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our 30,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

Daiichi Sankyo press release, blog etc

05/31/2018 - 13:03 Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
05/30/2018 - 13:18 Daiichi Sankyo U.S. subsidiary, Luitpold Pharmaceuticals, Inc., to Be Merged with Its Own Subsidiaries and Renamed
05/30/2018 - 12:50 Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
05/15/2018 - 18:25 Daiichi Sankyo Launches Naruvein Injection for Cancer Pain Treatment in Japan
05/14/2018 - 20:25 Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
05/10/2018 - 22:44 Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board
04/27/2018 - 00:43 Daiichi Sankyo to Reorganize Kitasato Daiichi Sankyo Vaccine into Specialized Manufacturing Subsidiary
04/25/2018 - 01:43 Daiichi Sankyo Announces Phase 1/2 Clinical Trial Results for DS-5141 (Therapeutic Agent for Duchenne Muscular Dystrophy) in Japan
04/17/2018 - 21:37 AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan
04/04/2018 - 22:27 Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
03/30/2018 - 01:57 Daiichi Sankyo Agrees to Modify the Terms of the Settlement Program for U.S. Olmesartan Products Liability Litigation
03/27/2018 - 00:22 Daiichi Sankyos HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW
03/07/2018 - 21:01 Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
02/26/2018 - 19:54 Daiichi Sankyo Announces NDA submission in Japan of Esaxerenone for Treatment of Hypertension
02/26/2018 - 18:48 Daiichi Sankyo Reports Rupture of Liquid Storage Tank at Kitamoto Facility of Kitasato Daiichi Sankyo Vaccine
02/22/2018 - 21:07 Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
02/22/2018 - 19:36 Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018
02/22/2018 - 01:15 Daiichi Sankyo Submits Application for Additional Indication and Dosage for Diagnogreen for Injection 25 mg in Japan